 Scott Sagel
Concepts (404)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 101 | 2025 | 1102 | 12.220 |
Why?
| | Aminophenols | 21 | 2025 | 158 | 4.010 |
Why?
| | Kartagener Syndrome | 24 | 2025 | 30 | 3.510 |
Why?
| | Ciliary Motility Disorders | 16 | 2025 | 24 | 3.420 |
Why?
| | Quinolones | 19 | 2025 | 135 | 3.230 |
Why?
| | Sputum | 26 | 2025 | 305 | 2.850 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 28 | 2025 | 335 | 2.790 |
Why?
| | Benzodioxoles | 12 | 2025 | 116 | 2.040 |
Why?
| | Lung | 26 | 2025 | 4106 | 1.760 |
Why?
| | Inflammation | 16 | 2023 | 2850 | 1.650 |
Why?
| | Respiratory Function Tests | 21 | 2024 | 561 | 1.560 |
Why?
| | Respiratory System Agents | 3 | 2022 | 23 | 1.470 |
Why?
| | Bronchiectasis | 4 | 2025 | 111 | 1.430 |
Why?
| | Pseudomonas Infections | 11 | 2025 | 221 | 1.340 |
Why?
| | Biomarkers | 25 | 2022 | 4092 | 1.330 |
Why?
| | Genetic Testing | 7 | 2021 | 451 | 1.320 |
Why?
| | Aminopyridines | 6 | 2022 | 102 | 1.320 |
Why?
| | Neonatal Screening | 5 | 2021 | 167 | 1.310 |
Why?
| | Cilia | 17 | 2025 | 172 | 1.300 |
Why?
| | Chloride Channel Agonists | 13 | 2025 | 85 | 1.250 |
Why?
| | Lung Diseases | 6 | 2023 | 785 | 1.240 |
Why?
| | Mycobacterium avium-intracellulare Infection | 3 | 2021 | 62 | 1.220 |
Why?
| | Anti-Bacterial Agents | 15 | 2024 | 1818 | 1.180 |
Why?
| | Child | 78 | 2025 | 21921 | 1.160 |
Why?
| | Azithromycin | 6 | 2024 | 97 | 1.110 |
Why?
| | Forced Expiratory Volume | 17 | 2025 | 488 | 1.080 |
Why?
| | Anti-Inflammatory Agents | 4 | 2020 | 476 | 1.050 |
Why?
| | Adolescent | 71 | 2025 | 21564 | 1.030 |
Why?
| | Mutation | 29 | 2022 | 3987 | 1.010 |
Why?
| | Bronchoalveolar Lavage Fluid | 7 | 2019 | 649 | 1.000 |
Why?
| | Trypsinogen | 3 | 2021 | 11 | 0.990 |
Why?
| | Disease Progression | 19 | 2025 | 2749 | 0.870 |
Why?
| | Vitamins | 2 | 2018 | 183 | 0.830 |
Why?
| | Humans | 135 | 2025 | 138651 | 0.790 |
Why?
| | Young Adult | 43 | 2025 | 13305 | 0.780 |
Why?
| | Female | 93 | 2025 | 73763 | 0.770 |
Why?
| | Indoles | 5 | 2025 | 414 | 0.770 |
Why?
| | Male | 90 | 2025 | 68260 | 0.760 |
Why?
| | Pyrazoles | 5 | 2025 | 425 | 0.760 |
Why?
| | Antioxidants | 3 | 2018 | 593 | 0.750 |
Why?
| | Pseudomonas aeruginosa | 11 | 2023 | 348 | 0.740 |
Why?
| | Ethambutol | 1 | 2021 | 25 | 0.700 |
Why?
| | Algorithms | 4 | 2021 | 1740 | 0.690 |
Why?
| | Rifampin | 1 | 2021 | 84 | 0.680 |
Why?
| | Breath Tests | 5 | 2022 | 76 | 0.630 |
Why?
| | Child, Preschool | 33 | 2025 | 11158 | 0.630 |
Why?
| | Mycobacterium avium Complex | 3 | 2021 | 87 | 0.610 |
Why?
| | Dyneins | 7 | 2024 | 34 | 0.580 |
Why?
| | Prospective Studies | 29 | 2025 | 7554 | 0.570 |
Why?
| | Longitudinal Studies | 14 | 2025 | 2844 | 0.570 |
Why?
| | Pyridines | 4 | 2025 | 494 | 0.570 |
Why?
| | Drug Combinations | 9 | 2025 | 346 | 0.560 |
Why?
| | Dietary Supplements | 3 | 2018 | 553 | 0.540 |
Why?
| | Malnutrition | 1 | 2018 | 82 | 0.530 |
Why?
| | C-Reactive Protein | 8 | 2022 | 415 | 0.530 |
Why?
| | Nontuberculous Mycobacteria | 3 | 2023 | 201 | 0.520 |
Why?
| | Leukocyte Elastase | 7 | 2023 | 75 | 0.520 |
Why?
| | Hospitalization | 3 | 2025 | 2235 | 0.500 |
Why?
| | Drug Discovery | 1 | 2016 | 144 | 0.470 |
Why?
| | Leukocyte L1 Antigen Complex | 5 | 2022 | 36 | 0.460 |
Why?
| | Specimen Handling | 3 | 2025 | 180 | 0.460 |
Why?
| | Infant | 23 | 2025 | 9574 | 0.450 |
Why?
| | Mycobacterium Infections, Nontuberculous | 4 | 2023 | 357 | 0.440 |
Why?
| | Infant, Newborn | 16 | 2025 | 6144 | 0.440 |
Why?
| | Adult | 44 | 2025 | 38201 | 0.430 |
Why?
| | Nitric Oxide | 5 | 2019 | 893 | 0.430 |
Why?
| | Metabolomics | 1 | 2019 | 689 | 0.430 |
Why?
| | Sweat | 5 | 2025 | 47 | 0.430 |
Why?
| | Retrospective Studies | 21 | 2025 | 15909 | 0.420 |
Why?
| | Automation | 1 | 2014 | 99 | 0.420 |
Why?
| | United States | 21 | 2025 | 14938 | 0.410 |
Why?
| | Granulocyte Colony-Stimulating Factor | 4 | 2022 | 88 | 0.410 |
Why?
| | Exocrine Pancreatic Insufficiency | 2 | 2010 | 22 | 0.400 |
Why?
| | Respiratory Tract Infections | 6 | 2025 | 383 | 0.400 |
Why?
| | Clinical Trials as Topic | 5 | 2015 | 1034 | 0.390 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2014 | 141 | 0.390 |
Why?
| | Blood Glucose | 5 | 2025 | 2239 | 0.380 |
Why?
| | Respiratory System | 4 | 2019 | 157 | 0.370 |
Why?
| | Microbiota | 5 | 2023 | 758 | 0.370 |
Why?
| | Tomography, X-Ray Computed | 7 | 2025 | 2698 | 0.360 |
Why?
| | Otorhinolaryngologic Diseases | 1 | 2011 | 16 | 0.360 |
Why?
| | Sensitivity and Specificity | 7 | 2021 | 1941 | 0.340 |
Why?
| | Vitamin K Deficiency | 1 | 2010 | 9 | 0.340 |
Why?
| | Staphylococcal Infections | 3 | 2019 | 387 | 0.340 |
Why?
| | Cohort Studies | 14 | 2025 | 5697 | 0.340 |
Why?
| | Vitamin A Deficiency | 1 | 2010 | 27 | 0.340 |
Why?
| | Cytokines | 6 | 2023 | 2080 | 0.330 |
Why?
| | Pyrrolidines | 3 | 2025 | 80 | 0.330 |
Why?
| | Severity of Illness Index | 10 | 2024 | 2851 | 0.320 |
Why?
| | Quality of Life | 5 | 2024 | 2954 | 0.320 |
Why?
| | Otitis Media with Effusion | 2 | 2025 | 20 | 0.320 |
Why?
| | Bronchoscopy | 2 | 2008 | 225 | 0.310 |
Why?
| | Secretory Leukocyte Peptidase Inhibitor | 1 | 2009 | 6 | 0.310 |
Why?
| | Treatment Outcome | 15 | 2025 | 10923 | 0.300 |
Why?
| | Lactoferrin | 1 | 2009 | 40 | 0.300 |
Why?
| | Bronchitis | 1 | 2009 | 41 | 0.300 |
Why?
| | Muramidase | 1 | 2009 | 79 | 0.300 |
Why?
| | Proteomics | 3 | 2022 | 1110 | 0.290 |
Why?
| | Vitamin D Deficiency | 1 | 2010 | 186 | 0.290 |
Why?
| | Tomography | 2 | 2018 | 43 | 0.280 |
Why?
| | Diverticulum | 1 | 2007 | 12 | 0.270 |
Why?
| | Tracheal Diseases | 1 | 2007 | 15 | 0.270 |
Why?
| | Administration, Oral | 3 | 2018 | 788 | 0.270 |
Why?
| | Tracheoesophageal Fistula | 1 | 2007 | 33 | 0.260 |
Why?
| | Genotype | 10 | 2025 | 1842 | 0.260 |
Why?
| | Data Interpretation, Statistical | 2 | 2021 | 364 | 0.260 |
Why?
| | Digestive System Surgical Procedures | 1 | 2007 | 106 | 0.250 |
Why?
| | Reproductive Health | 2 | 2017 | 90 | 0.250 |
Why?
| | Heterotaxy Syndrome | 2 | 2023 | 14 | 0.250 |
Why?
| | Phenotype | 8 | 2025 | 3139 | 0.240 |
Why?
| | Respiratory Distress Syndrome, Newborn | 2 | 2025 | 105 | 0.240 |
Why?
| | Proteins | 4 | 2024 | 1006 | 0.240 |
Why?
| | Pulmonary Atelectasis | 1 | 2025 | 16 | 0.240 |
Why?
| | Bacteria | 5 | 2023 | 867 | 0.230 |
Why?
| | Leukocyte Count | 5 | 2012 | 326 | 0.230 |
Why?
| | Middle Ear Ventilation | 1 | 2025 | 15 | 0.230 |
Why?
| | Meconium Ileus | 1 | 2024 | 5 | 0.230 |
Why?
| | Hearing Loss, Conductive | 1 | 2025 | 24 | 0.230 |
Why?
| | Interleukin-8 | 7 | 2012 | 271 | 0.220 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2005 | 133 | 0.220 |
Why?
| | Age Factors | 5 | 2020 | 3256 | 0.220 |
Why?
| | Chlorides | 3 | 2022 | 138 | 0.220 |
Why?
| | Probability | 3 | 2016 | 308 | 0.210 |
Why?
| | Glucose Tolerance Test | 5 | 2025 | 366 | 0.210 |
Why?
| | Situs Inversus | 1 | 2023 | 3 | 0.210 |
Why?
| | DNA, Bacterial | 4 | 2017 | 335 | 0.210 |
Why?
| | Rhinitis | 2 | 2019 | 171 | 0.210 |
Why?
| | Oropharynx | 3 | 2015 | 45 | 0.210 |
Why?
| | Cytoskeletal Proteins | 4 | 2024 | 156 | 0.210 |
Why?
| | Models, Neurological | 1 | 2006 | 249 | 0.210 |
Why?
| | Axonemal Dyneins | 4 | 2025 | 9 | 0.200 |
Why?
| | Follow-Up Studies | 7 | 2018 | 5112 | 0.200 |
Why?
| | Diabetes Mellitus | 2 | 2025 | 1068 | 0.200 |
Why?
| | Mucociliary Clearance | 2 | 2021 | 45 | 0.200 |
Why?
| | Sinusitis | 2 | 2019 | 237 | 0.200 |
Why?
| | Fetal Diseases | 1 | 2024 | 177 | 0.200 |
Why?
| | Neuronal Plasticity | 1 | 2006 | 302 | 0.200 |
Why?
| | Metagenome | 3 | 2013 | 149 | 0.190 |
Why?
| | Monitoring, Immunologic | 1 | 2002 | 22 | 0.190 |
Why?
| | Respiration Disorders | 1 | 2023 | 78 | 0.190 |
Why?
| | Genetic Markers | 4 | 2016 | 342 | 0.190 |
Why?
| | Uteroglobin | 1 | 2022 | 24 | 0.190 |
Why?
| | Calreticulin | 1 | 2022 | 28 | 0.190 |
Why?
| | HMGB Proteins | 1 | 2022 | 17 | 0.190 |
Why?
| | Chemistry, Clinical | 1 | 2002 | 6 | 0.190 |
Why?
| | Serum Amyloid A Protein | 2 | 2019 | 33 | 0.180 |
Why?
| | Peptide Hydrolases | 1 | 2023 | 112 | 0.180 |
Why?
| | Aspergillosis, Allergic Bronchopulmonary | 1 | 2021 | 11 | 0.180 |
Why?
| | Synapses | 1 | 2006 | 426 | 0.180 |
Why?
| | Hydrogen | 1 | 2022 | 75 | 0.180 |
Why?
| | Prognosis | 5 | 2018 | 3984 | 0.180 |
Why?
| | Body Mass Index | 5 | 2020 | 2349 | 0.180 |
Why?
| | Antibiotics, Antitubercular | 1 | 2021 | 36 | 0.180 |
Why?
| | Desmosine | 2 | 2012 | 6 | 0.170 |
Why?
| | Cross-Sectional Studies | 8 | 2024 | 5520 | 0.170 |
Why?
| | DNA Mutational Analysis | 5 | 2014 | 398 | 0.170 |
Why?
| | Rhodospirillaceae | 1 | 2020 | 4 | 0.170 |
Why?
| | Disease Management | 3 | 2015 | 622 | 0.170 |
Why?
| | Cross-Over Studies | 2 | 2021 | 556 | 0.170 |
Why?
| | Leptin | 1 | 2022 | 242 | 0.160 |
Why?
| | Glucose | 2 | 2023 | 1032 | 0.160 |
Why?
| | Quinolines | 3 | 2025 | 150 | 0.160 |
Why?
| | Mycobacterium abscessus | 1 | 2021 | 115 | 0.160 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2022 | 325 | 0.160 |
Why?
| | Patient Acuity | 1 | 2019 | 47 | 0.160 |
Why?
| | Antitubercular Agents | 1 | 2021 | 203 | 0.150 |
Why?
| | Proteome | 2 | 2022 | 469 | 0.150 |
Why?
| | Sleep Apnea, Central | 1 | 1999 | 11 | 0.150 |
Why?
| | Autonomic Nervous System Diseases | 1 | 1999 | 32 | 0.150 |
Why?
| | Alleles | 4 | 2017 | 887 | 0.150 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2018 | 748 | 0.150 |
Why?
| | Prevalence | 3 | 2025 | 2727 | 0.150 |
Why?
| | Pneumonia | 2 | 2017 | 644 | 0.150 |
Why?
| | Machine Learning | 1 | 2024 | 517 | 0.150 |
Why?
| | Predictive Value of Tests | 4 | 2023 | 2030 | 0.150 |
Why?
| | Respiratory Tract Diseases | 1 | 2020 | 181 | 0.150 |
Why?
| | Case-Control Studies | 6 | 2020 | 3523 | 0.140 |
Why?
| | Hypoglycemia | 1 | 2023 | 460 | 0.140 |
Why?
| | Oxidative Stress | 2 | 2018 | 1316 | 0.140 |
Why?
| | Diagnostic Techniques and Procedures | 1 | 2018 | 21 | 0.140 |
Why?
| | Air | 1 | 2018 | 43 | 0.140 |
Why?
| | Nutritional Status | 2 | 2018 | 352 | 0.140 |
Why?
| | Saliva | 2 | 2015 | 238 | 0.140 |
Why?
| | Hirschsprung Disease | 1 | 1999 | 89 | 0.140 |
Why?
| | Aptamers, Nucleotide | 1 | 2019 | 83 | 0.140 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2023 | 1244 | 0.140 |
Why?
| | Reproductive Health Services | 1 | 2017 | 18 | 0.140 |
Why?
| | Double-Blind Method | 3 | 2018 | 1949 | 0.140 |
Why?
| | Lipids | 1 | 2022 | 675 | 0.130 |
Why?
| | Respiration | 1 | 2018 | 207 | 0.130 |
Why?
| | Health Services Misuse | 1 | 2017 | 35 | 0.130 |
Why?
| | Tobramycin | 2 | 2023 | 52 | 0.130 |
Why?
| | Insulin | 2 | 2025 | 2448 | 0.130 |
Why?
| | Clofazimine | 1 | 2017 | 14 | 0.130 |
Why?
| | Neutrophils | 3 | 2015 | 1274 | 0.130 |
Why?
| | Coinfection | 2 | 2020 | 137 | 0.130 |
Why?
| | Body Height | 1 | 2017 | 196 | 0.130 |
Why?
| | Middle Aged | 16 | 2025 | 33604 | 0.130 |
Why?
| | Neurons | 1 | 2006 | 1601 | 0.130 |
Why?
| | Axoneme | 2 | 2013 | 9 | 0.130 |
Why?
| | Immunologic Tests | 1 | 2016 | 16 | 0.120 |
Why?
| | Sexual Health | 1 | 2017 | 59 | 0.120 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 236 | 0.120 |
Why?
| | Body Weight | 1 | 2020 | 992 | 0.120 |
Why?
| | Diagnostic Tests, Routine | 1 | 2016 | 110 | 0.120 |
Why?
| | Postoperative Complications | 1 | 2007 | 2722 | 0.120 |
Why?
| | Spirometry | 4 | 2015 | 263 | 0.120 |
Why?
| | Exome | 5 | 2014 | 235 | 0.120 |
Why?
| | Time Factors | 4 | 2018 | 6851 | 0.120 |
Why?
| | Patient Selection | 1 | 2019 | 676 | 0.110 |
Why?
| | Targeted Gene Repair | 1 | 2015 | 1 | 0.110 |
Why?
| | Dried Blood Spot Testing | 1 | 2016 | 121 | 0.110 |
Why?
| | Molecular Targeted Therapy | 1 | 2018 | 413 | 0.110 |
Why?
| | Zebrafish | 3 | 2013 | 496 | 0.110 |
Why?
| | Microtubule-Associated Proteins | 2 | 2013 | 195 | 0.110 |
Why?
| | Pedigree | 5 | 2013 | 511 | 0.110 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1746 | 0.110 |
Why?
| | Insulin Resistance | 1 | 2023 | 1222 | 0.110 |
Why?
| | Bacteria, Anaerobic | 2 | 2011 | 25 | 0.110 |
Why?
| | Hyperglycemia | 1 | 2018 | 358 | 0.110 |
Why?
| | Nasal Mucosa | 4 | 2019 | 106 | 0.110 |
Why?
| | Microscopy, Electron, Transmission | 4 | 2016 | 157 | 0.100 |
Why?
| | Survival Rate | 2 | 2018 | 1935 | 0.100 |
Why?
| | Ubiquinone | 2 | 2010 | 31 | 0.100 |
Why?
| | Homozygote | 3 | 2020 | 201 | 0.100 |
Why?
| | Antigens, Surface | 1 | 2013 | 154 | 0.100 |
Why?
| | Intestine, Small | 1 | 2014 | 156 | 0.100 |
Why?
| | Sexual Behavior | 1 | 2017 | 488 | 0.100 |
Why?
| | Venous Thromboembolism | 1 | 2017 | 324 | 0.100 |
Why?
| | Vital Capacity | 1 | 2014 | 312 | 0.100 |
Why?
| | GTP-Binding Proteins | 1 | 2013 | 152 | 0.100 |
Why?
| | Linear Models | 3 | 2024 | 852 | 0.100 |
Why?
| | Neutrophil Activation | 1 | 2013 | 85 | 0.100 |
Why?
| | Mycobacterium Infections | 1 | 2013 | 62 | 0.100 |
Why?
| | Precision Medicine | 1 | 2016 | 424 | 0.090 |
Why?
| | Elastin | 1 | 2012 | 79 | 0.090 |
Why?
| | DNA | 2 | 2018 | 1438 | 0.090 |
Why?
| | Proteolysis | 1 | 2012 | 174 | 0.090 |
Why?
| | Models, Statistical | 1 | 2016 | 663 | 0.090 |
Why?
| | Mycobacterium | 1 | 2013 | 110 | 0.090 |
Why?
| | Glycoproteins | 1 | 2013 | 354 | 0.090 |
Why?
| | Nasal Cavity | 1 | 2011 | 57 | 0.090 |
Why?
| | Turbinates | 1 | 2011 | 14 | 0.090 |
Why?
| | Tumor Suppressor Proteins | 1 | 2013 | 320 | 0.090 |
Why?
| | Polymerase Chain Reaction | 2 | 2011 | 1047 | 0.090 |
Why?
| | Biomarkers, Pharmacological | 1 | 2010 | 26 | 0.080 |
Why?
| | Dinoprost | 1 | 2010 | 46 | 0.080 |
Why?
| | Inflammation Mediators | 2 | 2005 | 513 | 0.080 |
Why?
| | Biopsy | 4 | 2015 | 1072 | 0.080 |
Why?
| | Leukocytes, Mononuclear | 1 | 2013 | 571 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1567 | 0.080 |
Why?
| | Metagenomics | 2 | 2021 | 177 | 0.080 |
Why?
| | Interprofessional Relations | 1 | 2012 | 290 | 0.080 |
Why?
| | Microbial Sensitivity Tests | 2 | 2021 | 351 | 0.080 |
Why?
| | Membrane Potentials | 2 | 2010 | 283 | 0.080 |
Why?
| | Morbidity | 2 | 2018 | 322 | 0.080 |
Why?
| | Chronic Disease | 2 | 2015 | 1805 | 0.080 |
Why?
| | Canada | 2 | 2024 | 407 | 0.080 |
Why?
| | Lung Injury | 1 | 2012 | 224 | 0.070 |
Why?
| | Pseudomonas | 2 | 2022 | 30 | 0.070 |
Why?
| | Exotoxins | 1 | 2008 | 16 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2490 | 0.070 |
Why?
| | Confidence Intervals | 1 | 2009 | 328 | 0.070 |
Why?
| | Administration, Inhalation | 2 | 2023 | 595 | 0.070 |
Why?
| | Heterozygote | 1 | 2009 | 305 | 0.070 |
Why?
| | Electric Impedance | 2 | 2018 | 111 | 0.070 |
Why?
| | Peroxidase | 2 | 2022 | 182 | 0.070 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 1 | 2007 | 38 | 0.070 |
Why?
| | Pregnancy Rate | 2 | 2017 | 67 | 0.070 |
Why?
| | RNA Precursors | 1 | 2008 | 155 | 0.070 |
Why?
| | Pregnancy | 4 | 2024 | 6829 | 0.070 |
Why?
| | Evidence-Based Medicine | 1 | 2011 | 745 | 0.070 |
Why?
| | Sequence Analysis, DNA | 3 | 2015 | 819 | 0.060 |
Why?
| | DNA-Binding Proteins | 1 | 2014 | 1471 | 0.060 |
Why?
| | Genomics | 2 | 2021 | 796 | 0.060 |
Why?
| | Diagnostic Errors | 1 | 2007 | 174 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 2 | 2018 | 2339 | 0.060 |
Why?
| | Biomedical Research | 1 | 2012 | 694 | 0.060 |
Why?
| | Reproducibility of Results | 3 | 2010 | 3307 | 0.060 |
Why?
| | RNA, Messenger | 1 | 2013 | 2815 | 0.060 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2005 | 28 | 0.060 |
Why?
| | Audiometry, Pure-Tone | 1 | 2025 | 30 | 0.060 |
Why?
| | Incidence | 2 | 2025 | 2747 | 0.060 |
Why?
| | Tympanic Membrane Perforation | 1 | 2025 | 17 | 0.060 |
Why?
| | Amoxicillin-Potassium Clavulanate Combination | 1 | 2024 | 16 | 0.060 |
Why?
| | Needs Assessment | 2 | 2017 | 379 | 0.060 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2025 | 97 | 0.050 |
Why?
| | Cephalosporins | 1 | 2024 | 45 | 0.050 |
Why?
| | Colorado | 2 | 2018 | 4555 | 0.050 |
Why?
| | Staphylococcus aureus | 1 | 2008 | 433 | 0.050 |
Why?
| | Reference Values | 2 | 2017 | 799 | 0.050 |
Why?
| | Vasodilator Agents | 1 | 2006 | 329 | 0.050 |
Why?
| | Exercise Tolerance | 1 | 2006 | 278 | 0.050 |
Why?
| | Microscopy, Electron | 2 | 2015 | 438 | 0.050 |
Why?
| | Piperazines | 1 | 2006 | 345 | 0.050 |
Why?
| | Diabetic Retinopathy | 1 | 2006 | 194 | 0.050 |
Why?
| | Registries | 2 | 2025 | 2073 | 0.050 |
Why?
| | Symptom Assessment | 1 | 2024 | 129 | 0.050 |
Why?
| | Immunity, Innate | 1 | 2009 | 824 | 0.050 |
Why?
| | Risk Factors | 3 | 2025 | 10252 | 0.050 |
Why?
| | Pancreatic Elastase | 1 | 2022 | 60 | 0.050 |
Why?
| | Glucagon | 1 | 2023 | 104 | 0.050 |
Why?
| | Cluster Analysis | 1 | 2024 | 517 | 0.050 |
Why?
| | Cell Count | 1 | 2002 | 325 | 0.050 |
Why?
| | Aspergillus fumigatus | 1 | 2021 | 25 | 0.050 |
Why?
| | Constipation | 1 | 2022 | 98 | 0.040 |
Why?
| | Nucleotides | 1 | 2022 | 127 | 0.040 |
Why?
| | Computer Simulation | 1 | 2006 | 996 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2025 | 980 | 0.040 |
Why?
| | Down Syndrome | 1 | 2007 | 484 | 0.040 |
Why?
| | Cough | 1 | 2001 | 125 | 0.040 |
Why?
| | Symptom Flare Up | 1 | 2020 | 37 | 0.040 |
Why?
| | Mutant Proteins | 1 | 2020 | 102 | 0.040 |
Why?
| | Observational Studies as Topic | 1 | 2021 | 121 | 0.040 |
Why?
| | Recovery of Function | 1 | 2024 | 665 | 0.040 |
Why?
| | Prediabetic State | 1 | 2023 | 248 | 0.040 |
Why?
| | Asthma | 2 | 2013 | 1888 | 0.040 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2017 | 1374 | 0.040 |
Why?
| | British Columbia | 1 | 2018 | 21 | 0.040 |
Why?
| | Fatal Outcome | 1 | 1999 | 309 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 984 | 0.030 |
Why?
| | Pilot Projects | 2 | 2017 | 1765 | 0.030 |
Why?
| | Hospitals | 1 | 2022 | 695 | 0.030 |
Why?
| | Early Medical Intervention | 1 | 2018 | 59 | 0.030 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2023 | 684 | 0.030 |
Why?
| | Ultrasonography, Prenatal | 1 | 1999 | 287 | 0.030 |
Why?
| | Age Distribution | 1 | 2017 | 393 | 0.030 |
Why?
| | Length of Stay | 1 | 2022 | 1238 | 0.030 |
Why?
| | Ontario | 1 | 2016 | 94 | 0.030 |
Why?
| | Radiography, Thoracic | 1 | 2017 | 172 | 0.030 |
Why?
| | Microscopy, Video | 1 | 2015 | 26 | 0.030 |
Why?
| | Respiratory Therapy | 1 | 2015 | 25 | 0.030 |
Why?
| | Radiography | 1 | 2017 | 841 | 0.030 |
Why?
| | Respiratory Syncytial Virus Vaccines | 1 | 2015 | 35 | 0.030 |
Why?
| | Regression Analysis | 1 | 2017 | 1017 | 0.030 |
Why?
| | Enterobacteriaceae | 1 | 2015 | 41 | 0.030 |
Why?
| | Staphylococcus | 1 | 2015 | 75 | 0.030 |
Why?
| | North America | 1 | 2015 | 304 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2017 | 5803 | 0.030 |
Why?
| | Enterobacteriaceae Infections | 1 | 2015 | 43 | 0.030 |
Why?
| | Hypertension, Pulmonary | 1 | 2006 | 1924 | 0.030 |
Why?
| | Pneumococcal Vaccines | 1 | 2015 | 135 | 0.030 |
Why?
| | Counseling | 1 | 2017 | 392 | 0.030 |
Why?
| | Genotyping Techniques | 1 | 2014 | 73 | 0.030 |
Why?
| | Sex Factors | 1 | 2020 | 2044 | 0.030 |
Why?
| | Genetic Therapy | 1 | 2016 | 314 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1482 | 0.030 |
Why?
| | Planarians | 1 | 2013 | 1 | 0.030 |
Why?
| | Chlamydomonas | 1 | 2013 | 3 | 0.030 |
Why?
| | Societies, Medical | 1 | 2018 | 839 | 0.030 |
Why?
| | Xenopus laevis | 1 | 2013 | 107 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2014 | 553 | 0.020 |
Why?
| | Open Reading Frames | 1 | 2013 | 132 | 0.020 |
Why?
| | Cytoplasm | 1 | 2013 | 270 | 0.020 |
Why?
| | Genes, Recessive | 1 | 2012 | 78 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 2049 | 0.020 |
Why?
| | Computer Communication Networks | 1 | 2012 | 33 | 0.020 |
Why?
| | Placebos | 1 | 2012 | 198 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 346 | 0.020 |
Why?
| | Superoxides | 1 | 2013 | 217 | 0.020 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2012 | 142 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2014 | 370 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2013 | 385 | 0.020 |
Why?
| | Airway Remodeling | 1 | 2012 | 63 | 0.020 |
Why?
| | DNA Barcoding, Taxonomic | 1 | 2011 | 22 | 0.020 |
Why?
| | Biota | 1 | 2011 | 35 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2012 | 395 | 0.020 |
Why?
| | Logistic Models | 1 | 2016 | 2065 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2013 | 858 | 0.020 |
Why?
| | Autoantigens | 1 | 2013 | 422 | 0.020 |
Why?
| | Influenza Vaccines | 1 | 2015 | 536 | 0.020 |
Why?
| | Biofilms | 1 | 2013 | 265 | 0.020 |
Why?
| | Ion Channels | 1 | 2010 | 127 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2013 | 540 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2013 | 616 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 623 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2012 | 785 | 0.020 |
Why?
| | Genes, rRNA | 1 | 2007 | 42 | 0.020 |
Why?
| | gamma-Tocopherol | 1 | 2007 | 7 | 0.020 |
Why?
| | beta Carotene | 1 | 2007 | 20 | 0.020 |
Why?
| | Mexico | 1 | 2008 | 232 | 0.020 |
Why?
| | Genes, Bacterial | 1 | 2007 | 166 | 0.020 |
Why?
| | Micelles | 1 | 2007 | 39 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2013 | 1102 | 0.020 |
Why?
| | Protein Binding | 1 | 2013 | 2225 | 0.020 |
Why?
| | Biological Availability | 1 | 2007 | 137 | 0.020 |
Why?
| | Animals | 3 | 2013 | 37217 | 0.020 |
Why?
| | Leukocytes | 1 | 2008 | 307 | 0.020 |
Why?
| | ROC Curve | 1 | 2008 | 562 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2008 | 761 | 0.020 |
Why?
| | Sildenafil Citrate | 1 | 2006 | 59 | 0.020 |
Why?
| | Research Design | 1 | 2012 | 1118 | 0.020 |
Why?
| | Aged | 2 | 2017 | 24024 | 0.010 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 1045 | 0.010 |
Why?
| | Acute Disease | 1 | 2008 | 994 | 0.010 |
Why?
| | Sulfones | 1 | 2006 | 110 | 0.010 |
Why?
| | Genetic Carrier Screening | 1 | 2004 | 30 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2017 | 7677 | 0.010 |
Why?
| | Purines | 1 | 2006 | 179 | 0.010 |
Why?
| | Rats | 1 | 2013 | 5594 | 0.010 |
Why?
| | Infant Care | 1 | 2004 | 44 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2013 | 2590 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2007 | 2923 | 0.010 |
Why?
| | Infant Nutritional Physiological Phenomena | 1 | 2004 | 144 | 0.010 |
Why?
|
|
Sagel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|